long intergenic non-protein coding RNA 2106Genealiases: []
Q-omics provides the consensus-scored LINC02106 profile across patient tissues and cancer cell-line models. LINC02106 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02106 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, LINC02106 RNA expression shows 8,284 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where LINC02106 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02106 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02106 survival associations across molecular data types. LINC02106 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02106 RNA expression–survival associations across cancer types. High LINC02106 expression shows unfavorable associations in KIRC, UCEC, LGG, ACC and LIHC, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02106 RNA expression.
This table summarizes LINC02106 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02106. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02106 shows lower tumor expression in STAD, THCA, BRCA, COAD, HNSC and PRAD. The STAD box plot shows higher LINC02106 RNA expression in normal versus tumor tissue (log2 FC = −1.232, t-test p < 0.001).
This table shows molecular features associated with LINC02106 in patient tissues and cancer cell lines. In patient samples, LINC02106 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
